GET DAILY SIGNALSBioLineRx (BLRX): Analyst Targets Point to a Potential +1,051% Advance
Key Takeaways
- The central target of $22 is the arithmetic mean of two current, verifiable analyst price targets, which range from $18 to $26.
- At a recent price near $1.91, reaching $22 implies an upside of roughly 1,051%, an exceptionally large move.
- H.C. Wainwright's Joseph Pantginis maintains a Buy rating with a $26 target (October 2026); a second analyst carries an $18 target.
- The strongest support comes from APHEXDA's U.S. approval and the company's clinical-stage pipeline; the biggest risks are a sharp revenue decline and a very small market capitalization of about $9.8 million.
- Annual revenue fell from roughly $28.9 million in 2024 to about $1.2 million in 2025, underscoring execution risk.
- Explore additional pages for this ticker's Major News, Today's Price Move, Forecast, and Earnings to stay current on developments.
- For broader AI-driven market coverage, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Coverage of this micro-cap remains limited. Two current targets stand out: a $26 target from H.C. Wainwright analyst Joseph Pantginis, maintained with a Buy rating in October 2026, and an $18 target from another firm. The arithmetic mean of these two figures is $22, which serves as the central target here. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. The range is wide on an absolute basis, and relative to a sub-$2 share price it is extreme, reflecting how much of the modeled value depends on pipeline success rather than near-term fundamentals. An earlier $12 target from JonesTrading appears to have been superseded in current aggregator data. With only two analysts, the “consensus” should be read cautiously: it signals optimism but rests on a very small sample.
Current Market Position and Path Toward the Target
Shares of BLRX closed near $1.91 on November 3, 2026, toward the lower end of a 52-week range of $1.90 to $3.95. Reaching the $22 central target would require an advance of about 1,051%, an extremely large move that is far outside typical one-year expectations for most equities. The theoretical path would depend on a fundamental re-rating: renewed or expanded commercial traction for APHEXDA, positive clinical data from motixafortide in sickle-cell disease or pancreatic cancer, or progress with the preclinical GLIX1 program. None of these outcomes is assured, and the gap between the current share price and analyst targets reflects a high-risk, high-reward, binary-style profile.
What Could Support a Move Toward the Target
APHEXDA's regulatory approval gives BioLineRx a commercial asset, and analysts' targets imply meaningful potential value in the broader pipeline. Motixafortide is being studied across multiple indications, and the company retains rights in certain territories while partnering elsewhere, including a licensing arrangement covering parts of Asia. A positive clinical readout, a new partnership or milestone payment, or evidence that operating losses are narrowing could improve sentiment and re-rate the shares. Improved revenue visibility after the sharp 2025 decline would also help close the valuation gap.
What Could Prevent the Target From Being Reached
The obstacles are substantial. Revenue collapsed from about $28.9 million in 2024 to roughly $1.2 million in 2025, and 2026 consensus points to only about $1.6 million, suggesting commercialization has struggled. The company remains unprofitable, and a market capitalization near $9.8 million leaves little room for error. Dilution risk is a recurring concern for early-stage biotechs, and negative or inconclusive clinical data would likely weigh on shares. Finally, the sheer size of the move required means the target should be viewed as a long-dated, scenario-driven objective rather than a near-term path.
Technical Levels and Market Structure
The stock sits just above its 52-week low of $1.90, which now functions as a key support level; a decisive break below it would leave little in the way of prior historical support. On the upside, the stock faces resistance near $3.95, the 52-week high, with psychological round numbers such as $2 and $3 likely acting as interim barriers. With average daily volume measured in the tens of thousands of shares, this is a thinly traded name where price moves can be amplified by limited liquidity. From what I see, monitoring these levels closely makes sense given the volatility.
Time Horizon and What Investors Should Monitor
Analyst price targets are typically framed around a 12-month horizon, though no specific horizon is stated for every target here, and the wide range suggests divergent assumptions about pipeline outcomes. Investors should watch the company's next earnings report, estimated for late November 2026, along with any updates on APHEXDA commercialization, clinical data from the motixafortide and GLIX1 programs, cash runway, and any financing or partnership announcements. Revisions to the two analyst targets will also be an important signal.
AI Daily Buy/Sell Signals
I have found Tickeron's AI Daily Buy/Sell Signals helpful for monitoring names like this. The system uses artificial intelligence to track thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions and technical behavior. For a thinly traded, high-volatility stock, these signals offer an objective way to complement fundamental research and stay on top of potential shifts.
Final Assessment
The $22 central target is the mean of two analyst price targets ranging from $18 to $26, and it sits more than 1,000% above the recent share price of roughly $1.91. The gap reflects a scenario in which BioLineRx's pipeline and APHEXDA franchise deliver substantial value, but current fundamentals—sharply lower revenue, ongoing losses, and a micro-cap valuation—argue for caution. The upside potential is real if clinical and commercial milestones materialize, yet the target is far from a guarantee. Investors should weigh the wide analyst range, the small sample of coverage, and the company's thin liquidity before drawing conclusions, and should monitor earnings, clinical data, and cash runway closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BLRX's RSI Indicator slumps oversold zone
The RSI Oscillator for BLRX moved into overbought territory on November 03, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for BLRX just turned positive on October 23, 2026. Looking at past instances where BLRX's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.
Following a +5.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLRX advanced for three days, in 194 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
BLRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BLRX as a result. In 73 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BLRX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.691) is normal, around the industry mean (3.051). P/E Ratio (0.000) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (7.868) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. BLRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical development company
Industry Biotechnology
Advertisement